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Abstract
Background: Non-V600E BRAF mutated colorectal cancer (CRC) is a rare disease entity with specific clinical features.
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often
harbor a KRAS or NRAS mutation. Notably, median overall survival is longer than in wild-type BRAF CRC. Little is
known about treatment possibilities in these patients.
Case presentation: We present the case of a 59 year old patient with a rare mutation in BRAF codon 594, who
progressed rapidly on all classical therapies but experienced a clear and long lasting response on treatment with
Regorafenib.
Conclusion: Little is known about therapies that can be effective in the rare non-V600E BRAF mutated CRCs. We
present a patient who had a definite response to treatment with Regorafenib. There are no predictive markers that
define a subset of CRC patients who benefit most from Regorafenib. The specific features of this non-V600E BRAF
mutated CRC may be relevant in the exploration of predictive biomarkers for the efficacy of Regorafenib.
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Background
BRAF is a serine/threonine protein kinase involved in the
MAP kinase/ERK-signaling pathway. In this pathway, RAS
small guanidine triphosphatase activates the RAF family
of proteins (ARAF, BRAF and CRAF). These proteins
phosphorylate MEK1/2 proteins, which in turn activate
ERKs (extracellular signal-regulated kinases). These regu-
late a variety of substrates, including multiple transcrip-
tion factors, thus controlling several key cellular activities.
Dysregulation of this pathway induces many elements of
tumorigenesis [1, 2].
In CRC it is well known that patients with a BRAF
V600E mutation have a poor prognosis. In recent years,
extensive molecular testing has led to the diagnosis of
other mutations in the BRAF gene. BRAF codon 594
and 596-mutations occur in less than 1–2% of CRC
patients, which accounts for 22% of all BRAF mutations.
Higher incidences have been described and racial differ-
ences have been suggested [3, 4].
Non-V600E BRAF mutated tumors differ in molecular
and pathological characteristics as well as phenotypically
[3, 4]. They are less likely to have microsatellite instabil-
ity than BRAF V600E mutated CRC and more likely to
harbor a KRAS or NRAS mutation. Median overall sur-
vival is longer than in wild type BRAF CRC with a me-
dian of 60,7 months demonstrated in a group of 101
patients [4].
Little is known about treatment possibilities in these
patients. Some reports with conflicting results have been
published on therapy with anti-EGFR antibodies [5, 6].
Case presentation
A 59-year-old man was diagnosed in July 2014 with a
rectal tumor and associated solitary lung metastasis,
cT3N1bM1a. He was treated with Folfox-Bevacizumab
during 2 months, followed by radiochemotherapy: 25 × 1,
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8 Gy in combination with oxaliplatin and 5FU. In De-
cember 2014, he underwent a total mesorectal excision
(TME) together with a video-assisted thoracoscopic re-
section (VATS) of the lung lesion. The final pathological
stage was ypT3N0M1 adenocarcinoma of the rectum
and the patient underwent further treatment with
Folfox-bevacizumab until the end of March.
In May 2015, at the time of planned restoration of
bowel continuity, a relapse was noted in the liver and a
resection of segment 4B was performed.
In November 2015, new liver lesions and a peripan-
creatic mass were found and for the first time a slight
elevation of carcinoembryonic antigen (CEA) - 5 μg/L -
was noted. Two months after initiation of Folfiri-
Bevacizumab, progressive disease (PD) was found on CT
scan (with growth of the peripancreatic mass and liver
metastases and occurrence of an aortocaval lymph node)
. The CEA level had risen to 26 μg/L.
In the meantime, molecular analysis was performed
and the tumor proved to be KRAS-NRAS wild type
(WT), BRAF mutant with a specific mutation, c.1781A >
G (p.(Asp594Gly)) in exon 15 (Next Generation Sequen-
cing (Massively parallel targeted re-sequencing Somatic
1 Multiplicom MASTR assay). Immunohistochemical
staining showed no loss of expression of mismatch re-
pair proteins, suggesting microsatellite stability (Anti-
bodies used: Clone ES05 (Novocastra) for MLH1, Clone
6219–1129 (Roche) for MSH2, Clone EP49 (DAKO) for
MSH6 and Clone A16–4 (Roche) for PMS2).
Therapy with Folfox-Cetuximab was not successful:
there was further progression after 2 months of treat-
ment with occurrence of new liver metastases and a fur-
ther growth of the peripancreatic lesion and aortocaval
lymph nodule. CEA increased to 51 μg/L.
In March 2016, Regorafenib was started at a dose of
160 mg/day (21 days on, 7 days off ) while at the same
time treatment of the liver metastases with selective in-
ternal radiation therapy (SIRT) with Yttrium-90 in com-
bination with stereotactic beam radiation therapy
(SBRT) for the para-aortic lymph nodes was planned.
Because of a hand-foot skin reaction, treatment with
topical corticosteroids and keratolytics was started and a
dose modification was made to regorafenib 120mg/d
after 1 treatment cycle. In June 2016, when the treat-
ment with Regorafenib was interrupted in order to
proceed to radiotherapy, the CEA level had already
dropped to 11 μg/L. SBRT of the para-aortic lymph
nodes was administered at a dose of 3 × 8 Gy. CEA was
6 μg/L before selective treatment with Yttrium-90 in the
right liver lobe. The patient suffered from bulbitis post
radioembolization. In July 2016 a complete remission
(CR) was seen in the liver – also in the left liver lobe,
which had not been treated with Yttrium-90. CEA had
dropped to 5 μg/L.
Regorafenib was stopped in September 2016 after 6
months of treatment.
Re-evaluation at the end of January 2017 showed new
lymph nodes in the periampullary region and a rise in
CEA level to 12 μg/L. Regorafenib was re-initiated at a
dose of 120mg/d, 3 weeks on, 1 week off. The hand-foot
skin reaction was more severe, leading to a personalised
treatment schedule - 10 days on/7 days off - in order to
increase patient tolerability. Treatment with Regorafenib
resulted in normalization of CEA (2 μg/L) and response
on CT-scan (Fig. 1) and therapy was stopped in August
2017.
In February 2018, the patient consulted with complaints
suggesting gastric outlet obstruction. Endoscopy revealed
bulbitis. Chronic inflammation post radioembolization
was suspected, but tumor cells were found in the biopsies.
CEA had risen to 19 μg/L. A palliative Billroth II resection
was performed and tumoral deposits were found both in
the duodenum and the antrum.
Regorafenib was reintroduced in April 2018 at a dose
of 120 mg/d using the same schedule as in 2017. Re-
evaluation in July 2018 showed new adenopathies and a
further increase in CEA to 43 μg/L. Shortly thereafter
the patient developed jaundice because of biliary
obstruction due to a lesion in the liver hilum. Biliary
stenting was not possible, but the lesion responded very
well to radiotherapy (5 × 4 Gy), resulting in an amelior-
ation of the jaundice. The patient declined further
interventions.
Overall, treatment with Regorafenib with therapeutic
breaks resulted in clinical response, both biochemically
and radiologically. Disease control was possible during
more than 24months in this patient with a rare BRAF
mutation. A timeline highlighting the most important
disease characteristics, the disease evolution and the
therapeutic interventions can be found in Fig. 2.
Discussion and conclusions
Patients with Non-V600E BRAF mutated CRC are rare and
little is known about treatment possibilities in these pa-
tients. Because of the low frequency of these mutations, it
will be difficult to investigate the impact of treatment regi-
mens in a prospective (randomized controlled) trial. We
present a case of a patient with a specific mutation,
c.1781A >G (p.(Asp594Gly)) in exon 15, with a clear re-
sponse and a long benefit on treatment with Regorafenib.
Regorafenib (BAY 73–4506; Bayer Schering Pharma
AG, Berlin, Germany) is an oral small-molecule multiki-
nase inhibitor that is active against several angiogenic re-
ceptor tyrosine kinases (RTKs: VEGFR-1, VEGFR-2,
VEGFR-3, TIE-2), oncogenic RTKs (c-KIT, RET), stro-
mal RTKs (PDGFR-B, FGFR1), and intracellular signal-
ing kinases (c-RAF/RAF-1, BRAF, BRAFV600E) [7]. A
Phase III trial (CORRECT) has demonstrated significant
Callebout et al. BMC Cancer          (2019) 19:567 Page 2 of 5
Fig. 1 Evolution of periampullary adenopathies on reintroduction of regorafenib. A In january 2017 periampullary adenopathies were seen on
follow-up CT-scan. B CT-scan after 6 months of treatment with regorafenib shows a partial response
Fig. 2 Timeline 2014–2018: Disease characteristics, disease evolution (left column) and therapeutic interventions (right column)
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clinical efficacy of Regorafenib in patients with refractory
or advanced mCRC [8]. The main effect of Regorafenib on
metastatic colorectal cancer in the CORRECT trial
seemed to be disease stabilisation, rather than tumor
shrinkage. An analysis of the Kaplan–Meier curves for
PFS in the CORRECT trial suggests that there may be a
distinct subgroup of mCRC patients who are more likely
to respond to Regorafenib treatment [7]. Data on the
BRAF status of patients were not provided. In vitro activ-
ity of Regorafenib in RKO cell lines harboring a V600E
BRAF mutation has been shown, but data are scarce and
there is no evidence of in vitro activity in other BRAF mu-
tation [9]. Analysis of potential predictive biomarkers for
efficacy of Regorafenib is ongoing, but may prove to be
difficult because of the nonspecific activity of Regorafenib
across a wide range of angiogenic, oncogenic, stromal, and
intracellular signaling kinases [7].
The patient we present was a young man with a left-
sided (rectal), intermediate grade, microsatellite stable
tumor: elements that have often been described in
Non-V600E BRAF mutated CRC patients [4]. On the other
hand, the absence of a KRAS-NRAS mutation and more
importantly the rapid progression upon relapse are less
typical features [4].
Our patient had a clear response on Regorafenib. Sug-
gestions about the most interesting pathways to explore
as potentially predictive biomarkers for treatment with
Regorafenib may be derived from the distinct character-
istics of this Non-V600E BRAF mutated tumor.
Recently, four consensus molecular subtypes (CMS)
with specific features have been described in colorectal
cancer: CMS1 (MSI Immune): hypermutated, microsat-
ellite unstable tumors with strong immune activation;
CMS2 (Canonical): epithelial, chromosomally unstable
tumors with marked WNT and MYC signaling activa-
tion; CMS3 (Metabolic): epithelial tumors with evident
metabolic dysregulation and CMS4 (Mesenchymal): tu-
mors with prominent transforming growth factor β acti-
vation, stromal invasion, and angiogenesis [10, 11].
Classical BRAF mutated tumors are most often found in
the CMS 1 group [4, 10].
The epithelial to mesenchymal transition (EMT) is an
important component of cancer progression. Changes of
EMT have been associated with features of advanced
disease including metastasis, resistance to chemotherapy,
and generation of cancer cells with stem cell-like charac-
teristics [12, 13]. EMT could be impaired in microsatel-
lite instable (MSI) tumors [13]. Similarly, mucinous
tumors have been linked to local more than distant re-
currence [14]. Thus, the finding that MSI-H and mucin-
ous tumors are more epithelial than mesenchymal seems
biologically consistent [14].
Mucinous histology is seen less often in Non-V600E
BRAF mutated CRC and these tumors are usually
microsatellite stable [3]. It is possible that CRC with a
BRAF mutation occurring at codon 594 specifically rep-
resent a mesenchymal phenotype highly dependent on
the EMT signature, as can be found in the CMS 4 group
[4, 10]. Regorafenib has been shown to target EMT in
vitro in colorectal cancer [15]. Furthermore, a greater
progression free survival benefit for regorafenib in
patients defined as ‘high-risk’ subgroup, according to
Marisa molecular subtypes (C4 and C6), corresponding
with an upregulation of EMT pathway, has been ob-
served [16–18]. This is one possible explanation for the
clear therapeutic advantage seen in our patient that
should be further explored.
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